Myocarditis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Myocarditis - Pipeline Review, H1 2016', provides an overview of the Myocarditis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myocarditis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocarditis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Myocarditis - The report reviews pipeline therapeutics for Myocarditis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Myocarditis therapeutics and enlists all their major and minor projects - The report assesses Myocarditis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Myocarditis Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Myocarditis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Myocarditis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Myocarditis Overview 6 Therapeutics Development 7 Pipeline Products for Myocarditis - Overview 7 Pipeline Products for Myocarditis - Comparative Analysis 8 Myocarditis - Therapeutics under Development by Companies 9 Myocarditis - Therapeutics under Investigation by Universities/Institutes 10 Myocarditis - Pipeline Products Glance 11 Early Stage Products 11 Myocarditis - Products under Development by Companies 12 Myocarditis - Products under Investigation by Universities/Institutes 13 Myocarditis - Companies Involved in Therapeutics Development 14 CEL-SCI Corporation 14 GlaxoSmithKline Plc 15 Myocarditis - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Molecule Type 21 Drug Profiles 22 CEL-1000 - Drug Profile 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Cell Therapy to Activate IL-10 for Autoimmune Myocarditis and Inflammation - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Cellular Immunotherapy to Target Flt3L for Autoimmune Myocarditis - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 chagas disease vaccine - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 OBR-5340 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecule to Inhibit Coxsackievirus B3 3C Protease for Myocarditis - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Myocarditis - Recent Pipeline Updates 30 Myocarditis - Dormant Projects 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 32 Disclaimer 33
List of Tables
Number of Products under Development for Myocarditis, H1 2016 7 Number of Products under Development for Myocarditis - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Products under Investigation by Universities/Institutes, H1 2016 13 Myocarditis - Pipeline by CEL-SCI Corporation, H1 2016 14 Myocarditis - Pipeline by GlaxoSmithKline Plc, H1 2016 15 Assessment by Monotherapy Products, H1 2016 16 Number of Products by Stage and Target, H1 2016 18 Number of Products by Stage and Mechanism of Action, H1 2016 20 Number of Products by Stage and Molecule Type, H1 2016 21 Myocarditis Therapeutics - Recent Pipeline Updates, H1 2016 30 Myocarditis - Dormant Projects, H1 2016 31
List of Figures
Number of Products under Development for Myocarditis, H1 2016 7 Number of Products under Development for Myocarditis - Comparative Analysis, H1 2016 8 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy Products, H1 2016 16 Number of Products by Targets, H1 2016 17 Number of Products by Stage and Targets, H1 2016 17 Number of Products by Mechanism of Actions, H1 2016 19 Number of Products by Stage and Mechanism of Actions, H1 2016 19 Number of Products by Molecule Types, H1 2016 21
Global Bio polyethylene terephthalate (PET) market size is likely to be valued at USD 12.6 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing preference of biopolymers in numerous applications coupled with favorable goverRead More...
Global automotive electronics market size forecast is likely to reach USD 279.96 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing application scope of these equipments is estimated to drive industry growth. Increasing iRead More...
Global automotive relay market is anticipated to reach USD 12 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising need for high-frequency signals in automotive industry is expected to drive demand. These relays enhance drivRead More...
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous industRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.